Pfizer Inc. (NYSE:PFE) Jefferies London Healthcare Conference November 20, 2024 4:00 AM ET
Company Participants
Dave Denton – CFO
Andrew Baum – Chief Strategy and Innovation Officer, EVP
Conference Call Participants
Akash Tewari – Jefferies
Akash Tewari
Good to start. All right. Good morning, everyone. This is day two of our London Healthcare Conference. My name is Akash Tewari. I am a pharma and biotech analyst here at Jefferies. I hope you all enjoyed day one. It was a little rainy, but still fun.
I have the pleasure of hosting the Pfizer management team: Dave Denton; and for the first time, Andrew Baum, sitting on the other side of the podium. Maybe, Dave, I’ll hand it over for you for any brief introductory remarks, and then we’ll get started.
Dave Denton
Yes. Thank you, and thank you for hosting us today. And importantly, thank you for your interest in Pfizer. I’ll be very brief because we’ll get right into Q&A. But I just want to state that, obviously, we went into 2024 as a company really with a keen focus on execution. I think we’ve continued to drive delivery of both top line and bottom line throughout this year.
We continue to be very focused on enhancing and growing our Oncology franchise as well as continuing to optimize the cost structure of the organization coming off the COVID highs, now at a revenue base of about $60 billion. We’re excited about the future, and we’re hoping that today, we’ll get a chance to both talk about what we’re doing here and now, but importantly, the growth and financial outlook of the company going forward. Thank you.
Question-and-Answer Session
Q – Akash Tewari
Understood. So Dave, we’ll start with kind of the question that I think we’ve all gotten over the last few
Read the full article here